A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection

Transplantation

Volumn 71, Issue 1, 2001, Pages 53-58

  Casadei, Domingo H ^a,b   Del C Rial, María ^a,b   Opelz, Gerhard ^c   Golberg, Julio C ^a,b   Argento, Jorge A ^a,b   Greco, Gabriela ^a,b   Guardia, Olga E ^a,b   Haas, Emilio ^d   Raimondi, Eduardo H ^d  

^a Instituto de Nefrologia Buenos Aires ar   (Argentina)

^b Institute of Nephrology   (Argentina)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; OKT 3; STEROID;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION;

EID: 0035863090     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200101150-00009     Document Type: Article

References (34)

1. OKT3 monoclonal antibodies induce interleukin-6 and interleukin-10: A possible cause of lymphoproliferative disorders associated with transplantation
2. High-dose intravenous immunoglobulin: New therapy as a rescue for treatment for grafted kidneys
3. Preliminary results from a randomized, blinded, placebo-controlled trial of intravenous gammaglobulin plus pulse steroids for the treatment of acute rejection episodes in renal allograft recipients
4. Intravenous polyclonal immunoglobulins (IVIg): What use in transplantation?
5. Plasmapheresis, intravenous cytomegalovirus-specific immunoglobulin and reversal of antibody-mediated rejection in a pediatric renal transplant recipient: A case report
6. Impact of the Banff97 classification for histological diagnosis of rejection on clinical outcome and renal function parameters after kidney transplantation
7. Complementary data about the inhibitory effects of intravenous immunoglobulin in vitro and in vivo
8. An overview of Orthoclone OKT3
9. Ligands and biological activities of soluble Fc gamma receptors
10. Regulation of B-cell activation and antigen presentation by Fc receptors
11. Natural anti-immunoglobulin autoantibodies: Irrelevant by-products or immunoregulatory molecules
12. Presensitization and HLA match influence the predictive power of pretransplant serum IgA and IgA-anti-Fab autoantibodies in kidney graft recipients
13. Highdose intravenous immunoglobulin modifies complement-mediated in vivo clearance
14. Normal human immunoglobulins for intravenous use (IVIg) delay hyperacute xenograft rejection through F(ab′)2-mediated anti-complement activity
15. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin: Attenuation of acute, complement-dependent immune damage in a guinea pig model
16. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments
17. Regulation of complement activity by immunoglobulin
18. Production of IL-receptor antagonist and IL-1 beta by peripheral blood mononuclear cells is differentially regulated
19. Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin)
20. Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3:5-monophosphate levels, resulting in suppression of tumor necrosis factor alpha and interleukin-1 production
21. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo
22. Autoantibodies to cytokines: Friends or foes?
23. Distribution and characterization of autoantibodies to interleukin 1α in normal human sera
24. Anti-cytokine nature of human immunoglobulin: One possible mechanism of the clinical effect of intravenous therapy
25. Dimmer formation in immunoglobulin preparations and speculations on the mechanisms of action of intravenous immunoglobulin in autoimmune diseases
26. Cytomegalovirus immune globulin intravenous (human) administration modulates immune response to alloantigens in sensitized renal transplant candidates
27. Kidney transplantation in a positive cross-match patient treated with intravenous gammaglobulin in high dose (IVIgHD)
28. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulin (IVIg): A potential tool for transplantation of immunized patients
29. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients
30. Immunomodulation of kidney and heart transplants by anti-idiotypic antibodies
31. Lymphokine production induced by streptococcal pyrogenic exotoxin-A is selectively down-regulated by pooled human IgG
32. Down-regulation of cytokine production and IL-2 receptor expression by pooled human IgG